The COVID Treatment QuickStart Consortium partners with governments to rapidly introduce and scale access to COVID-19 oral antiviral therapies in vulnerable and high-risk populations presenting with mild to moderate symptoms within five days of symptom onset through a public health test-and-treat model. Our top priorities are:

1. Ensuring treatments are accessible in all parts of the world;
2. Preparing for potential future COVID-19 surges; and

QuickStart Milestones

Implementation Updates
QuickStart supports Ministries of Health to develop robust monitoring and evaluation systems at the sub-national and national levels, identifying opportunities to strengthen the COVID-19 test-and-treat response by:

1. Supporting facility assessments, operational and distribution planning, the development of training materials, and clinical guidelines;
2. Scaling and decentralizing access to oral antiviral treatment; and
3. Strengthening case finding strategies in countries that have introduced test-and-treat programs.

**Self-Test Donations**

QuickStart is establishing a self-test product introduction program to catalyze self-testing, increase case finding, and scale access to treatment within five days of symptom onset within our ten partner countries.

Scale-up of self-testing for COVID-19 is an urgent need to tackle alongside persistently low primary vaccination and booster rates in many countries. The donation of these fast, proven, and reliable COVID-19 antigen tests will help ensure patients have access to rapid and reliable diagnoses.
Members of the QuickStart team from Duke University attended the 76th World Health Assembly in Geneva. Dr. Krishna Udayakumar, along with Precious Matsosoa and Kate D. Warren, participated in the Devex-hosted session titled "COVID-19 and beyond: The future of global pandemic preparedness." During the session, he emphasized the importance of integrating test-and-treat services into primary care, specifically highlighting the significance of diagnostics and testing within healthcare systems. The integration of test-and-treat services into primary care is a critical component for achieving comprehensive capabilities in pandemic preparedness and response. The recognition of the pressing need for such integration further highlighted the importance of ensuring effective and accessible healthcare services during times of crisis.

Access a recording of the panel [here](#).

---

**Upcoming Events**

**IAS Conference on HIV Science**

**23 - 26 July 2023**

**Brisbane, Australia**

Engage with members of the QuickStart team and learn about integrating COVID-19 testing and treatment programs into HIV care in in Zambia, at the [IAS 2023](#) poster exhibition.
Market News

Generic COVID-19 Oral Antiviral to Increase Access in LMICs

The Medicines Patent Pool (MPP) has just announced the signing of sublicense agreements with seven companies based in four countries to manufacture and supply the generic versions of Shionogi’s COVID-19 oral antiviral, ensitrelvir in 117 low- and-middle-income countries (LMICs).

Ensitrelvir is a once-a-day oral treatment for COVID-19 which has received Emergency Use Authorization in Japan and fast-track designation by the United States Food and Drug Administration. Global phase 3 clinical trials are ongoing.

These new agreements are the products of a voluntary licence agreement signed by MPP and Shionogi to facilitate early access to affordable ensitrelvir in LMICs. Learn more in the latest press release.

CBS News: CDC tracking new COVID variant EU.1.1 (23 June 2023)


World Health Organization: Countries set out way forward for continued negotiations on global agreement on pandemic prevention, preparedness, and response (17 June 2023)

About Us

The COVID Treatment Quick Start Consortium brings together Duke University,Americares, the Clinton Health Access Initiative (CHAI), and COVID Collaborative as implementing partners, with support from
The Open Society Foundations, Pfizer and the Conrad N. Hilton Foundation. The consortium supports governments in introducing and scaling up access to new and effective COVID-19 oral antiviral therapies in high-risk populations. Learn more: covidquickstart.org.